全球蜱传脑炎灭活疫苗市场规模（按病毒类型、最终用户、区域范围和预测）

蜱传脑炎灭活疫苗市场规模及预测

蜱传脑炎灭活疫苗市场规模在 2024 年价值 3 亿美元，预计到 2032 年将达到 4.8 亿美元，2026 年至 2032 年的复合年增长率为 7.2%。

推动全球蜱传脑炎灭活疫苗市场的因素

蜱传脑炎灭活疫苗市场的驱动因素可能受到多种因素的影响。这些因素包括：

盛行率和发生率：蜱传脑炎在地方流行区和新发病区的盛行率和发生率对疫苗接种需求影响很大。发病率的上升往往促使疫苗宣传活动加强。

认知与教育：进行公众意识宣传活动与教育项目，强调结核病的危害，可以影响疫苗接种需求。随着人们对结核病及其可能后果的认识不断提高，人们更有可能为自己和家人接种疫苗。

免疫接种计画和政府政策：将结核病疫苗纳入国家免疫接种计画以及免疫法规的执行，可对消费者需求产生重大影响。疫苗接种回扣和补贴也有助于鼓励接种。

旅行和旅游业趋势：与旅行相关的商务旅行 (TBE) 很常见，尤其是在欧洲和亚洲部分地区。前往这些地区的旅行和旅游业成长可能会导致寻求结核病疫苗接种的旅客需求增加。

研发：发展的动力将是疫苗技术的开发，以提高疫苗的安全性、有效性和给药的便利性，使疫苗接种更加可靠，并为更多的人接种疫苗。

疫情爆发和流行：如果爆发结核病，这可能会导致社会焦虑加剧，并增加人们对接种疫苗的需求，因为人们会尝试接种疫苗来预防这种疾病。

气候变迁和生态学因素：传播结核病的蜱虫的分布和流行程度可能因气候和生态学因素的变化而改变，从而可能扩大该疾病的地理范围并增加以前未受影响地区的疫苗接种需求。

医疗保健基础设施：疫苗接种覆盖率和市场需求可能会受到医疗保健基础设施的可近性和可用性的影响，例如疫苗接种诊所和有资格接种结核病疫苗的医疗保健人员。

保险覆盖范围：结核性脑炎疫苗的保险覆盖范围和报销政策可能会影响疫苗的可用性和可负担性，进而影响市场需求。

限制全球灭活蜱传脑炎疫苗市场的因素

蜱传脑炎灭活疫苗市场可能面临多种限制和挑战，包括：

教育和认知不足：公众对蜱传疾病和疫苗获取管道的无知可能会阻碍该行业的扩张。在结核病不常见的地区，由于缺乏对危害的认知，疫苗需求可能会减少。

地域限制：结核病主要流行于亚洲和欧洲部分地区。结核病发病率较低的地区对疫苗的需求可能有限，这可能会阻碍市场扩张。

经济因素：经济因素可能会阻碍疫苗的取得，尤其是在低收入国家。疫苗宣传活动的成本以及疫苗本身也可能阻碍疫苗的普及，尤其是在医疗保健服务匮乏的地区。

监管障碍：疫苗分发和核准的严格监管可能会阻碍市场扩张。在许多国家和地区，疫苗製造商获得监管部门的批准既昂贵又耗时。

疫苗接种犹豫：对疫苗有效性和安全性的错误讯息和担忧都可能导致接种犹豫，从而影响结核病疫苗的接种率并阻碍市场扩张。

与其他预防措施的竞争：疫苗的引入可能面临其他预防措施的竞争，如穿防护衣、使用驱虫剂等。此外，竞争疫苗和不同的预防结核病的方法可能会限制市场扩张。

季节性：结核病发生率通常在蜱虫最活跃的某些季节上升。由于这种季节性，疫苗的市场需求可能会在全年波动。

供应链问题：疫苗的生产、配送和储存可能非常复杂，并可能为市场参与企业带来问题。在结核病流行地区，尤其是在偏远或资源匮乏的地区，维持稳定的供应链可能非常困难。

目录

第一章 灭活蜱传脑炎疫苗的全球市场介绍

• 市场采用
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

4. 蜱传脑炎灭活疫苗的全球市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

5. 全球灭活蜱传脑炎疫苗市场（依病毒类型划分）

• 概述
• 西伯利亚TBE病毒
• 远东TBE病毒
• 欧洲TBE病毒

6. 全球蜱传脑炎灭活疫苗市场（依最终用户）

• 概述
• 旅行者疫苗
• 儿童疫苗
• 成人疫苗

7. 全球灭活蜱传脑炎疫苗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 其他的
  • 拉丁美洲
  • 中东和非洲

8. 全球蜱传脑炎灭活疫苗市场竞争格局

• 概述
• 各公司市场排名
• 重点发展策略

第九章 公司简介

• GlaxoSmithKline plc.
• London Travel Clinic
• Superdrug Health Clinic
• Pfizer Inc.
• Encephalitis Global, Inc
• The Cochrane Collaboration
• Sonic HealthPlus Pty Ltd
• Merck & Co., Inc
• Baxter International Inc
• Hawaii BIoTech, Inc

第十章 重大进展

• 产品发布/开发
• 合併与收购
• 业务扩展
• 伙伴关係与合作

第十一章 附录

• 相关调查

Tick-Borne Encephalitis Inactivated Vaccine Market Size And Forecast

Tick-Borne Encephalitis Inactivated Vaccine Market size was valued at USD 300 Million in 2024 and is projected to reach USD 480 Million by 2032, growing at a CAGR of 7.2% during the forecast period 2026-2032.

Global Tick-Borne Encephalitis Inactivated Vaccine Market Drivers

The market drivers for the Tick-Borne Encephalitis Inactivated Vaccine Market can be influenced by various factors. These may include:

Prevalence and Incidence: The demand for vaccinations can be strongly influenced by the prevalence and incidence of TBE in areas where it is endemic or emerging. Increasing incidence rates frequently prompts more immunization campaigns.

Awareness and Education: Vaccination demand may be influenced by public awareness campaigns and educational programs highlighting the dangers of TBE. People may seek vaccinations for themselves and their families as they become more aware of the illness and its possible effects.

Immunization Programs and Government Policies: Including TBE vaccines in national immunization programs or enforcing vaccination laws can have a significant impact on consumer demand. Reimbursements or subsidies for the cost of vaccinations might also encourage uptake.

Travel and Tourism Trends: Travel-related business travel (TBE) is common in several areas, especially in portions of Europe and Asia. Travelers seeking protection against the disease may find a greater need for TBE vaccinations as a result of increased travel and tourism to these regions.

Research and Development: By boosting vaccination confidence and reaching a wider audience, developments in vaccine technology, such as those that enhance safety, efficacy, and convenience of administration, can propel market expansion.

Outbreaks and Epidemics: When TBE occurs, there may be a surge in public anxiety and a need for vaccinations as people try to vaccinate against the illness.

Climate Change and Ecological Factors: TBE-carrying tick distribution and prevalence can be altered by changes in climate and ecological factors. This could lead to an expansion of the disease's geographic range and a greater requirement for immunization in previously unaffected areas.

Healthcare Infrastructure: Vaccination rates and market demand may be impacted by the accessibility and availability of healthcare infrastructure, such as vaccination clinics and medical personnel qualified to give TBE vaccines.

Insurance Coverage: A TBE vaccination's insurance coverage and reimbursement policies may have an impact on accessibility and affordability, which in turn may have an effect on market demand.

Global Tick-Borne Encephalitis Inactivated Vaccine Market Restraints

Several factors can act as restraints or challenges for the Tick-Borne Encephalitis Inactivated Vaccine Market. These may include:

Limited Education and Awareness: The general public's ignorance about tick-borne illnesses and the accessibility of vaccines can impede the expansion of the industry. There might not be as much demand for the vaccine in areas where TBE is uncommon because of a lack of knowledge about the hazards.

Geographic Restrictions: TBE is mostly endemic in some parts of Asia and Europe. The demand for the vaccine may be restricted in regions with low incidence of TBE, which could hinder efforts to expand the market.

Economic Factors: Access to vaccines may be hampered by financial limitations, especially in low-income nations. Adoption may be hampered by the expense of immunization campaigns and the vaccine itself, particularly in areas with little access to healthcare.

Regulatory Obstacles: Tight regulations pertaining to vaccination distribution and approval may impede market expansion. For vaccine producers, obtaining regulatory clearances in many nations and areas can be expensive and time-consuming.

Vaccine reluctance: Misinformation and worries about the effectiveness and safety of vaccines can all lead to vaccination reluctance. This may have an effect on TBE vaccination uptake and impede market expansion.

Competition from Other Preventive Measures: The adoption of vaccines may face competition from other preventive measures like wearing protective clothing and using insect repellents. Furthermore, rival vaccinations or different methods of preventing TBE could restrict market expansion.

Seasonality: When tick activity is at its highest, TBE incidence frequently rises during specific seasons. The market demand for vaccinations may fluctuate throughout the year as a result of this seasonality.

Supply Chain Difficulties: Vaccine manufacture, delivery, and storage can be complicated, which might present problems for market participants. It might be challenging to keep a steady supply chain when TBE is common, particularly in isolated or resource-constrained places.

Global Tick-Borne Encephalitis Inactivated Vaccine Market Segmentation Analysis

The Global Tick-Borne Encephalitis Inactivated Vaccine Market is segmented on the basis of Virus Type, End User, And Geography.

Tick-Borne Encephalitis Inactivated Vaccine Market, By Virus Type

• Siberian TBE Virus
• Far Eastern TBE Virus
• European TBE Virus

Based on Virus Type, The market is segmented into Siberian TBE Virus, Far Eastern TBE Virus, and European TBE Virus. The three types of TBEV are TBEV-European, TBEV-Siberian, and TBEV-Far Eastern (previously Russian spring-summer encephalitis virus), which differ in geography and disease presentation. TBEV usually causes febrile disease, which may be followed by severe neurological disorders, such as encephalitis and meningitis. Some virus strains, like TBEV-Far Eastern, have a high mortality rate, and many survivors suffer from long-term sequelae.

Tick-Borne Encephalitis Inactivated Vaccine Market, By End User

• Traveler Vaccines
• Pediatric Vaccines
• Adult Vaccines

Based on End User, The market is segmented into Traveler Vaccines, Pediatric Vaccines and Adult Vaccines. Travelers who anticipate high-risk exposures, such as working or camping in forested regions or farmland, adventurous travel, or long stays in TBE-endemic nations.

Tick-Borne Encephalitis Inactivated Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Regional Analysis, The Global Tick-Borne Encephalitis Inactivated Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. TBE is endemic in a few areas in Europe and Asia, ranging from eastern France to northern Japan, and from northern Russia to Albania. The country with the most reported cases is Russia. Western Siberia, Slovenia, and the Baltic States have recorded the highest disease incidence.

Key Players

• The major players in the Tick-Borne Encephalitis Inactivated Vaccine Market are:
• GlaxoSmithKline plc.
• London Travel Clinic
• Superdrug Health Clinic
• Pfizer Inc.
• Encephalitis Global Inc.
• The Cochrane Collaboration
• Sonic HealthPlus Pty Ltd.
• Merck & Co. Inc.
• Baxter International Inc.
• Hawaii Biotech Inc.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL TICK-BORNE ENCEPHALITIS INACTIVATED VACCINE MARKET

• 1.1 Introduction of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL TICK-BORNE ENCEPHALITIS INACTIVATED VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL TICK-BORNE ENCEPHALITIS INACTIVATED VACCINE MARKET, BY VIRUS TYPE

• 5.1 Overview
• 5.2 Siberian TBE Virus
• 5.3 Far Eastern TBE Virus
• 5.4 European TBE Virus

6 GLOBAL TICK-BORNE ENCEPHALITIS INACTIVATED VACCINE MARKET, END USER

• 6.1 Overview
• 6.2 Traveler Vaccines
• 6.3 Pediatric Vaccines
• 6.4 Adult Vaccines

7 GLOBAL TICK-BORNE ENCEPHALITIS INACTIVATED VACCINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL TICK-BORNE ENCEPHALITIS INACTIVATED VACCINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 GlaxoSmithKline plc.
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 London Travel Clinic
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Superdrug Health Clinic
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Pfizer Inc.
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Encephalitis Global, Inc
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 The Cochrane Collaboration
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Sonic HealthPlus Pty Ltd
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Merck & Co., Inc
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Baxter International Inc
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Hawaii Biotech, Inc
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research